Ternary Health
Post-Infectious & Fatigue Syndromes · Fibromyalgia

Fibromyalgia

Fibromyalgia is not a diagnosis of exclusion. It is a real, characterizable disorder of central sensitization — and the things commonly missed alongside it can change everything.

About Fibromyalgia

What we mean when we say Fibromyalgia.

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, cognitive symptoms, and heightened sensitivity to stimuli. It is now understood as a disorder of central pain processing and nervous system sensitization rather than a peripheral musculoskeletal condition.

Estimates place global prevalence at 1.0 to 2.7%, with strong female predominance. Despite its size, fibromyalgia care remains fragmented and frequently dismissive. Many patients are given the diagnosis and little else.

The most important clinical reality of fibromyalgia is that it is rarely the only thing going on. Small fiber neuropathy, ME/CFS, hypermobility, autonomic dysfunction, sleep disorders, and post-viral syndromes are frequently coexistent and frequently unaddressed.

Prevalence

1.0–2.7% of the global population. Approximately 80–200 million people worldwide depending on diagnostic criteria.

The path to diagnosis

Why Fibromyalgia gets missed.

1.0–2.7%
Global prevalence
Peer-reviewed prevalence studies
~40–50%
Of fibromyalgia patients have small fiber neuropathy on biopsy
Small fiber neuropathy in fibromyalgia literature

Fibromyalgia is the diagnosis people receive when nothing else fits — and then nothing else gets pursued. The label closes a workup that should have continued. The conditions frequently underlying or coexisting with fibromyalgia go unevaluated, and patients are left with a name for their pain but no plan beyond pregabalin and physical therapy.

  1. 01
    Fibromyalgia is over-diagnosed as a label and under-investigated as a workup. Patients receive the diagnosis and no further evaluation — no small fiber neuropathy screening, no autonomic testing, no sleep architecture analysis, no connective tissue or mast cell evaluation.
  2. 02
    Small fiber neuropathy is present on skin biopsy in roughly 40 to 50 percent of patients diagnosed with fibromyalgia. When SFN is the actual driver, the management changes substantially — but the biopsy is rarely ordered.
  3. 03
    ME/CFS criteria are met in a substantial subset of fibromyalgia patients, and the post-exertional malaise pattern is rarely asked about specifically. Patients are told to exercise more when graded exercise is contraindicated by their underlying physiology.
  4. 04
    Sleep architecture disorders, autonomic dysfunction, and hypermobility are all common in the fibromyalgia population and all change management when identified. None are part of a routine fibromyalgia workup.
How we approach it

The Ternary Health approach to Fibromyalgia.

01

Treat fibromyalgia as a starting point, not an endpoint. Pursue the specific drivers in your case — small fiber neuropathy, autonomic dysfunction, sleep architecture, central sensitization markers, post-infectious triggers, connective tissue involvement.

02

Evaluate for ME/CFS criteria specifically. The post-exertional malaise pattern is the single most important clinical distinction, because it determines whether graded exercise is appropriate or harmful.

03

Audit pharmacologic and non-pharmacologic management against the specific drivers identified, rather than offering one-size-fits-all fibromyalgia treatment. Low-dose naltrexone, autonomic-targeted therapies, sleep architecture interventions, and SFN-directed treatment options each have specific evidence bases.

04

Screen the broader systemic picture — mast cell involvement, hypermobility, dysautonomia, post-infectious patterns — that frequently coexists with fibromyalgia and frequently explains incomplete response to fibromyalgia-directed management.

Signals we look for

The Ternary Signal Library for Fibromyalgia.

Our Signal Library for Fibromyalgia codifies the specific patterns that matter — central sensitization markers, small fiber and autonomic findings, sleep architecture, and post-infectious or connective tissue patterns. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.

Central Sensitization Markers
  • Widespread pain index and symptom severity scoring
  • Allodynia and hyperalgesia distribution mapping
  • Quantitative sensory testing where available
  • Central nervous system imaging findings where pursued
  • Pain catastrophizing and central modulation indicators
Small Fiber & Autonomic Workup
  • Skin punch biopsy with intraepidermal nerve fiber density
  • Autonomic reflex screen — sudomotor, cardiovagal, adrenergic
  • Tilt-table or 10-minute stand test for orthostatic intolerance
  • Quantitative sudomotor axon reflex testing where indicated
  • Etiologic SFN workup — autoimmune, metabolic, genetic, infectious
Sleep Architecture
  • Polysomnography findings — sleep stages, arousal patterns
  • Alpha-delta intrusion characteristic of fibromyalgia sleep
  • Sleep apnea screening — frequently coexistent
  • Restless legs and periodic limb movements
  • Sleep timing, duration, and refreshment quality
Comorbid Post-Infectious & Connective Tissue Patterns
  • ME/CFS criteria evaluation — post-exertional malaise specifically
  • Post-infectious trigger history — viral, bacterial, tick-borne
  • Hypermobility screening — Beighton score, connective tissue findings
  • Mast cell involvement — multi-system mediator pattern
  • Long COVID overlap in post-2020 onset cases
The nine-stage workflow, applied

How a Fibromyalgia case moves through our workflow.

Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.

Stage 01 · 0–2
Qualification
Fit screen confirms fibromyalgia diagnosis or strongly consistent presentation, access to prior workup records, and current treatment status. Onset history and pre-existing conditions matter for case prioritization.
Stage 02 · 3–7
Intake & data aggregation
Records pull emphasizes prior neurology and rheumatology workups, any SFN or autonomic testing performed, sleep studies, and medication trial history. Symptom timeline built with attention to post-exertional patterns and triggering events.
Stage 03 · 7–10
Case structuring
Case schema populated. ME/CFS criteria evaluated in parallel. SFN, autonomic, and sleep workup gaps identified. Comorbid screening across mast cell, connective tissue, and post-infectious patterns initiated.
Stage 04 · 10–14
Signal analysis
The Ternary Signal Library for fibromyalgia is applied. Typical case activates 14–20 signals across central sensitization, small fiber, sleep, and comorbidity domains. Each signal evaluated for your specific presentation.
Stage 05 · 14–19
Evidence retrieval
Literature scan emphasizes SFN-in-fibromyalgia biopsy series, ME/CFS overlap data, low-dose naltrexone trials, autonomic-targeted therapy evidence, and the post-infectious fibromyalgia literature. Condition-specific Evidence Matrix refreshed.
Stage 06 · 19–24
Pathway mapping
Pathway map built across neurology with SFN expertise, autonomic medicine, sleep medicine, rheumatology, pain management, and where indicated mast cell or connective tissue specialists. Specialists mapped from our Specialist Graph.
Stage 07 · 24–28
Synthesis & plan construction
Every option weighed against the three questions (Evidence × Personalization × Action), then prioritized and sequenced. Dependencies encoded as a directed graph — SFN biopsy informs etiologic workup, which informs immunomodulatory consideration, which informs autonomic and sleep strategy.
Stage 08 · 28–32
Delivery & calibration
Findings call with attention to PEM status, exercise prescription appropriateness, and management sequencing. Your priorities and constraints update the plan before finalization.
Stage 09 · 32–62
Execution support
30 days of asynchronous follow-up through the typical fibromyalgia workup sequence — neurology for SFN, autonomic medicine, sleep medicine, and any indicated comorbid specialist consultations. Outcomes captured into the Ledger.
Deliverables

What you receive.

  • A written case synthesis characterizing the specific drivers in your fibromyalgia presentation
  • Integration of pain, autonomic, sleep, and comorbidity findings into a single view
  • Small fiber neuropathy and autonomic workup audit with specific testing recommendations
  • ME/CFS criteria evaluation and exercise-prescription appropriateness assessment
  • Specialist identification for SFN-capable neurology, autonomic medicine, and comorbid workup
  • A written action plan and follow-up support as you implement it
What a Ternary report adds

What a Precision Deep Dive provides for Fibromyalgia.

A Ternary Health Precision Deep Dive for fibromyalgia goes beyond the label to characterize the specific drivers in your case: small fiber neuropathy screening, autonomic involvement, sleep architecture, central sensitization markers, and overlap with ME/CFS, hEDS, and post-infectious syndromes. We audit pharmacologic, non-pharmacologic, and emerging treatment evidence.

See the published sample reports · read the Ternary Method

Frequently coexisting conditions

What we look for alongside Fibromyalgia.

Patients with Fibromyalgia frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.

Common questions — Fibromyalgia

What prospective Fibromyalgia clients ask most.

I have fibromyalgia. Why would I need a deep dive?
Because fibromyalgia as a label closes a workup that should have continued. Roughly 40 to 50 percent of patients with this diagnosis have small fiber neuropathy on biopsy — which changes management. A substantial subset meet ME/CFS criteria — which changes whether exercise is appropriate. Many have unaddressed autonomic, sleep, or mast cell involvement. The diagnosis isn't wrong; the workup is usually incomplete.
Should I be exercising?
The single most important question to answer first. If you have post-exertional malaise — symptoms worsening 12 to 48 hours after exertion, lasting days — graded exercise can cause meaningful harm. If you don't have PEM, structured movement is part of nearly every effective plan. The Ternary report makes that determination explicitly and builds the activity prescription accordingly.
Do I need a confirmed diagnosis before applying?
A fibromyalgia diagnosis or a clinical picture consistent with the ACR criteria is preferred. If you've been told you 'might have fibromyalgia' but the workup is incomplete, we can frame the differential and the evaluation pathway.
What about low-dose naltrexone?
Evaluated in every case. The evidence is modest but real, the side effect profile is favorable, and the prescribing landscape is uneven. We review whether LDN is appropriate for your presentation and how to access it if so.
How do you handle the overlap with ME/CFS and long COVID?
As coexistent conditions, not as competing diagnoses. The Ternary report evaluates each independently and synthesizes the management strategy across them. Many patients meet criteria for two or three of these simultaneously, and the plan reflects that reality.
Working through this on your own?

Three ways to engage Ternary on Fibromyalgia.

From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Fibromyalgia.

Start exploring

Free Brief

$0

A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.

Generated instantly, no charge.

Get a free Brief
Get organized

Launchpad

$400

A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.

Delivered in 3–5 business days

Start a Launchpad
Get answers

Precision Deep Dive

$6,500

A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.

September 2026 cohort

Apply for a Deep Dive
What a Ternary report looks like

See exactly what you receive.

A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Fibromyalgia — drawn from four research-validated patient profiles across four conditions.

Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.

Ready for clarity on your Fibromyalgia?

Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Fibromyalgia is generated instantly, no charge.